劉滄梧 研究員級主治醫師-論文

  1.  Tseng JS, Chiang CJ, Chen KC, Zheng ZR, Yang TY, Lee WC, Hsu KH, Huang YH, Liu TW, Hsia JY, Chang GC. Association of Smoking With Patient Characteristics and Outcomes in Small Cell Lung Carcinoma, 2011-2018. JAMA Netw Open. 2022 Mar 1; 5(3):e224830.
  2. Liao CT, Wen YW, Lee SR, Ng SH, Liu TW, Tsai ST, Tsai MH, Lin JC, Chien CY, Lou PJ, Wang CP, Chu PY, Leu YS, Tsai KY, Terng SD, Chen TM, Wang CH, Chen WC, Lee LY, Lin CY, Wang HM, Fang TJ, Huang SF, Kang CJ, Chang KP, Yen TC, Yang LY, Lin CH; Taiwan Oral Cavity Cancer Advisory Group. Clinical Outcomes of Taiwanese Patients with Resected Oral Cavity Squamous Cell Carcinoma Who Underwent Reconstruction with Free Versus Local Flaps. Ann Surg Oncol. 2022 Feb; 29(2):1130-1140. (IF=5.344; Rank: 82/242/ONCOLOGY – SCIE)
  3. Hu HM, Tsai HJ, Ku HY, Lo SS, Shan YS, Chang HC, Chao Y, Chen JS, Chen SC, Chiang CJ, Li AF, Wang HP, Wang TE, Bai LY, Wu MS, Chen LT, Liu TW*, Yang YH*. Survival outcomes of management in metastatic gastric adenocarcinoma patients. Sci Rep. 2021 Nov 30;11(1):23142. (*corresponding author) (IF=4.011, Rank: 15/69/MULTIDISCIPLINARY SCIENCES) (Project of Core Measurement Indicators)
  4. Dai HJ*, Yang YH, Wang TH, Lin YJ, Lu PJ, Wu CY, Chang YC, Lee YQ, Zhang YC, Hsu YC, Wu HH, Ke CR, Huang CJ, Wang YT, Yang SF, Hsiao KC, Liu KJ, Chen LT, Chang IS*, Chao KSC*, Liu TW*. Cancer registry coding via hybrid neural symbolic systems in the cross-hospital setting. IEEE Access. 2021 Jul 26; 9:112081-112096. (*corresponding author) (IF=3.367, Rank: 65/162/COMPUTER SCIENCE, INFORMATION SYSTEMS)
  5. Tutt ANJ, Garber JE, Kaufman B, Viale G, Fumagalli D, Rastogi P, Gelber RD, de Azambuja E, Fielding A, Balmaña J, Domchek SM, Gelmon KA, Hollingsworth SJ, Korde LA, Linderholm B, Bandos H, Senkus E, Suga JM, Shao Z, Pippas AW, Nowecki Z, Huzarski T, Ganz PA, Lucas PC, Baker N, Loibl S, McConnell R, Piccart M, Schmutzler R, Steger GG, Costantino JP, Arahmani A, Wolmark N, McFadden E, Karantza V, Lakhani SR, Yothers G, Campbell C, Geyer CE Jr; OlympiA Clinical Trial Steering Committee and Investigators (Tsang-Wu Liu). Adjuvant Olaparib for Patients with BRCA1- or BRCA2-Mutated Breast Cancer. N Engl J Med. 2021 Jun 24;384(25):2394-2405. (IF=91.253Rank: 1/167/MEDICINE, GENERAL & INTERNAL-SCIE) (BIG OlympiA Study)
  6. Martine Piccart, Marion Procter, Debora Fumagalli, Evandro de Azambuja, Emma Clark, Michael S Ewer, Eleonora Restuccia, Guy Jerusalem, Susan Dent, Linda Reaby, Hervé Bonnefoi, Ian Krop, Tsang-Wu Liu, Tadeusz Pieńkowski, Masakazu Toi, Nicholas Wilcken, Michael Andersson, Young-Hyuck Im, Ling Ming Tseng, Hans-Joachim Lueck, Marco Colleoni, Estefania Monturus, Mihaela Sicoe, Sébastien Guillaume, José Bines, Richard D Gelber, Giuseppe Viale, Christoph Thomssen, APHINITY Steering Committee and Investigators. Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer in the APHINITY Trial: 6 Years’ Follow-Up. J Clin Oncol. 2021 May; 39(13):1448-1457. (IF=32.956; Rank: 5/244/ ONCOLOGY) (BIG APHINITY Study)
  7. Lin MC, Leu YS, Chiang CJ, Ko JY, Wang CP, Yang TL, Chen TC, Chen CN, Chen HL, Liao CT, Tsai ST, Lin JC, Chu PY, Tsai KY, Tsai MH, Huang HC, Yang MH, Wu YH, Terng SD, Chien CY, Liu TW, Lee WC, Lou PJ*. Adequate Surgical Margins for Oral Cancer: A Taiwan Cancer Registry National Database Analysis. Oral Oncol. 2021 May; 119:105358. (IF=3.979, Rank: 5/91/DENTISTRY, ORAL SURGERY & MEDICINE – SCIE) (Project of Core Measurement Indicators)
  8. Lin SM, Ku HY, Hsu CY, Wang CL, Chang GC, Chang CS, Liu TW*. Long-Term Survival Effect of the Interval between Postoperative Chemotherapy and Radiotherapy in Patients with Completely Resected Pathological N2 Non-Small-Cell Lung Cancer. Cancers. 2021 May; 13(10):2494. (IF=6.126; Rank: 37/244/ONCOLOGY) (Project of Core Measurement Indicators)
  9. Pen SL, Shan YS, Hsiao CF, Liu TW, Chen JS, Ho CL, Chou WC, Hsieh RK, Chen LT, Ch’ang HJ. High Expression of Krüppel-like Factor 10 or Smad4 Predicts Clinical Benefit of Adjuvant Chemoradiotherapy in Curatively Resected Pancreatic Adenocarcinoma: From a Randomized Phase III Trial. Radiotherapy and Oncology. 2021 May; 158:146-54. (IF=4.856, Rank: 17/134/RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING – SCIE) (TCOG T3212 Study)
  10. Ku HY, Liu TW, Chang PY, et al. Development, Monitoring, and International Benchmarking of Quality Indicators for Cancer Diagnosis and Treatment: Lung Cancer, Colorectal Cancer, Breast Cancer, and Hepatoma. Journal of Healthcare Quality. 2021 Jan; 15(1): 54-59. (Project of Core Measurement Indicators)
  11. Tsai HJ, Tai J, Chen LT, Wu MS, Yeh KH, Lin CW, Wang TE, Wang HP, Yu FJ, Liou JM, Hsiao CF, Cheng TY, Yeh HJ, Ko CW, Chen MJ, Lo GH, Hsu PI, Chang CS, Hwang WS, Chuang SS, Lee HW, Shun CT, Chiu CF, Wang WM, Hsieh CY, Liu TW, Lin JT, Kuo SH and Cheng AL. A multicenter Prospective Study of First-line Antibiotic Therapy for Early-stage Gastric Mucosa-associated Lymphoid Tissue Lymphoma and Diffuse Large B-cell Lymphoma with Histological Evidence of Mucosa-associated Lymphoid Tissue. Haematologica. 2020 Jul; 105(7):e349-e354. (IF=7.570; Rank: 7/73/ HEMATOLOGY) (TCOG T3206 Study)
  12. Chen MH, Chou WC, CF, Jiang SS, Tsai HJ, Liu YC, Hsu C, Shan YS, YP, Hsich CH, Chiu CH, Liu TC, Cho SF, Liu TW, Chao Y. An Open-Label, Single-Arm, Two-Stage, Multicenter, Phase II Study to Evaluate the Efficacy of TLC388 and Genomic Analysis for Poorly Differentiated Neuroendocrine Carcinomas. Oncologist. 2019 Dec 18. (TCOG T1Z14 Study)
  13. Chen YJ, Tsai CY, Cheng YM, Nieh SW, Yeh TK, Chen CP, Wang MH, Chou LH, Chiu TY, Liu L, Ho C*, Chen CT*, Liu TW*. Impacts of Intralipid on Nanodrug Abraxane Therapy and on the Innate Immune System. Sci Rep. 2020 Feb 18; 10(1):2838. (*corresponding author) (IF=4.011, Rank: 15/69/MULTIDISCIPLINARY SCIENCES)
  14. Tsou HH, Yang HC, Hsiao CF, Hsiung CA, Liu TW, Chuang MH, Wu HY, Hsu YT, Tsui CW, Chen PJ, Cheng AL, Hsu C; Taiwan Cooperative Oncology Group. Cost-effectiveness of Preventing Hepatitis B Virus Reactivation in Patients with Lymphoma and Resolved HBV Infection. J Formos Med Assoc. 2020 Jan; 119(1 Pt 2):335-344. (IF=2.844; Rank: 35/160/MEDICINE, GENERAL & INTERNAL) (TCOG T1408 Study)
  15. Tseng CH, Tsuang BJ, Chiang CJ, Ku KC, Tseng JS, Yang TY, Hsu KH, Chen KC, Yu SL, Lee WC, Liu TW, Chan CC, Chang GC. The Relationship Between Air Pollution and Lung Cancer in Nonsmokers in Taiwan. J Thorac Oncol. 2019 May; 14(5):784-792. (IF=12.460; Rank: 11/223/ ONCOLOGY) (Project of Core Measurement Indicators)
  16. Lin SM, Ku HY, Chang TC, Liu TW, Chang CS and Hong JH. Outcomes for Cervical Cancer Patients Treated With Radiation in High-Volume and Low-Volume Hospitals. Int J Radiat Oncol Biol Phys. 2018 Sep. 1; 102(1):184-193. (IF=5.554; Rank: 11/128/RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING) (Project of Core Measurement Indicators)
  17. Hong RL, Hsiao CF, Ting LL, Ko JY, Wang CW, Chang JTC, Lou PJ, Wang HM, Tsai MH, Lai SC, Liu TW. Final results of a randomized phase III trial of induction chemotherapy followed by concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in patients with stage IVA and IVB nasopharyngeal carcinoma-Taiwan Cooperative Oncology Group (TCOG) 1303 Study. Ann Oncol. 2018 Sep 1;29(9):1972-1979. (IF=13.930; Rank: 9/223/ONCOLOGY) (TCOG T1303 Study)
  18. Yang HC, Tsou HH, Pei SN, Chang CS, Chen JH, Yao M, Lin SJ, Lin J, Yuan Q, Xia N, Liu TW, Chen PJ, Cheng AL, Hsu C; Taiwan Cooperative Oncology Group. Quantification of HBV core antibodies may help predict HBV reactivation in patients with lymphoma and resolved HBV infection. J Hepatol. 2018 Aug; 69(2):286-292. (IF=15.040; Rank: 4/80/ GASTROENTEROLOGY & HEPATOLOGY) (TCOG T1408 Study)
  19. Cheng YJ, Tsai MH, Chiang CJ, Tsai ST, Liu TW, Lou PJ, Liao CT, Lin JC, Chang JT, Tsai MH, Chu PY, Leu YS, Tsai KY, Terng SD, Chien CY, Yang MH, Hao SP, Wang CC, Tsai MH, Chen HHW, Kuo C, Wu YH. Adjuvant radiotherapy after curative surgery for oral cavity squamous cell carcinoma and treatment effect of timing and duration on outcome-A Taiwan Cancer Registry national database analysis. Cancer Med. 2018 Jul; 7(7):3073-3083. (IF=3.202; Rank: 110/222/ONCOLOGY)
  20. Hung YP, Chen MH, Lin JS, Hsiao CF, Shan YS, Chen YC, Chen LT, Liu TW, Li CP, Chao Y. The clinical impact of the novel tumor marker DR-70 in unresectable gastric cancer patients. J Chin Med Assoc. 2018 Jul; 81(7):593-598. (IF=1.660; Rank: 72/154/MEDICINE, GENERAL & INTERNAL) (TCOG T3211 Study)
  21. Hung YN, Wen FH, Liu TW, Chen JS, Tang ST. Hospice Exposure is associated with lower health care expenditures in Taiwanese cancer decedents’ last year of life: A population-based retrospective cohort study. J Pain Symptom Manag. 2018 Mar; 55(3):755-765.e5.
  22. Chien LH, Tseng TJ, Tsai FY, Wang JH, Hsiung CA, Liu TW*, Chang IS*. Patterns of age-specific socioeconomic inequalities in net survival for common cancers in Taiwan, a country with universal health coverage. Cancer Epidemiol. 2018 Jan 20; 53:42-48. (*corresponding author)
  23. Chao YK, Ku HY, Chen CY, Liu TW*. Induction Therapy Before surgery improves survival in patients with clinical T3N0 esophageal cancer: a nationwide study in Taiwan. Diseases of the Esophagus. 2017 Dec 1; 30(12):1-7. (*corresponding author) (Project of Core Measurement Indicators)
  24. Tseng CH, Chiang CJ, Tseng JS, Yang TY, Hsu KH, Chen KC, Wang CL, Chen CY, Yen SH, Tsai CM, Huang MS, Ho CC, Yu CJ, Tsai YH, Chen JS, Chou TY, Tsai MH, Chen HY, Su KY, Chen JJW, Chen HW, Yu SL, Liu TW, Chang GC. EGFR mutation, smoking, and gender in advanced lung adenocarcinoma. Oncotarget. 2017 Oct 12; 8(58):98384-98393.  (Project of Core Measurement Indicators)
  25. Lin SM, Ku HY, Chang TC, Liu TW*, Hong JH. The prognostic impact of overall treatment time on disease outcome in uterine cervical cancer patients treated primarily with concomitant chemoradiotherapy: a nationwide Taiwanese cohort study. Oncotarget. 2017 Jul 27; 8(49): 85203-85213. (*corresponding author) (Project of Core Measurement Indicators)
  26. von Minckwitz G, Procter M, de Azambuja E, Zardavas D, Benyunes M, Viale G, Suter T, Arahmani A, Rouchet N, Clark E, Knott A, Lang I, Levy C, Yardley DA, Bines J, Gelber RD, Piccart M, Baselga J; APHINITY Steering Committee and Investigators (Liu TW). Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer. N Engl J Med. 2017 Jul 13; 377(2):122-131. (BIG APHINITY Study)
  27. Liu TW, Wen FH, Wang CH, Hong RL, Chow JM, Chen JS, Chiu CF, Tang ST. Terminally Ill Taiwanese cancer patients’ and family caregivers’ agreement on patterns of life-sustaining treatment preferences is poor to fair and declines over a decade: Results from two independent cross-sectional studies. Journal of Pain and Symptom Management. 2017 Jul; 54(1):35-45.e4.
  28. Chien LH, Tseng TJ, Chen CH, Jiang HF, Tsai FY, Liu TW, Hsiung CA, Chang IS. Comparison of annual percentage change in breast cancer incidence rate between Taiwan and the United States-A smoothed Lexis diagram approach. Cancer Medicine. 2017 Jul; 6(7):1762-1775.
  29. Kuan FC, Lai CH, Ku HY, Wu CF, Hsieh MC, Liu TW, Yeh CY, Lee KD. The survival impact of delayed surgery and adjuvant chemotherapy on stage II/III rectal cancer with pathological complete response after neoadjuvant chemoradiation. International Journal of Cancer. 2017 Apr ; 140(7):1662-1669. (Project of Core Measurement Indicators)
  30. Liao CT, Wen YW, Yang LY, Lee SR, Ng SH, Liu TW, Tsai ST, Tsai MH, Lin JC, Chen PR, Lou PJ, Wang CP, Chu PY, Hwang TZ, Leu YS, Tsai KY, Terng SD, Chen TM, Wang CH, Chien CY, Chen WC, Lee LY, Lin CY, Wang HM, Hsieh CH, Tsao CK, Fang TJ, Huang SF, Kang CJ, Chang KP, Yen TC. Comparative clinical outcomes of Taiwanese patients with resected buccal and tongue squamous cell carcinomas. Oral Oncology. 2017 Apr; 67:95-102.
  31. Hung YN, Liu TW, Wen FH, Chou WC, Tang ST. Escalating health care expenditures in cancer decedents’ last year of life: A decade of evidence from a retrospective population-based cohort study in Taiwan. Oncologist. 2017 Apr; 22(4):460-469.
  32. Liao CT, Wen YW, Lee SR, Liu TW, Tsai ST, Tsai MH, Lin JC, Lou PJ, Chu PY, Leu YS, Tsai KY, Terng SD, Chen TM, Wang CH, Chien CY, Chen WC, Lee LY, Lin CY, Wang HM, Ng SH, Lin CH, Fang TJ, Huang SF, Kang CJ, Chang KP, Yang LY, Yen TC, Taiwan Oral Cancer Advisory Group. Clinical Outcomes of Taiwanese Patients with cT4 Oral Cavity Squamous Cell Carcinoma: Toward the Identification of the Optimal Initial Treatment Approach for cT4b Patients. Annals of Surgical Oncology. 2017 Mar; 24(3):785-793.
  33. Liao CT, Chen HN, Wen YW, Lee SR, Ng SH, Liu TW, Tsai ST, Tsai MH, Lin JC, Lou PJ, Wang CP, Chu PY, Leu YS, Tsai KY, Terng SD, Chen TM, Wang CH, Chien CY, Chen WC, Lee LY, Lin CY, Wang HM, Lin CH, Fang TJ, Huang SF, Kang CJ, Chang KP, Yang LY, Yen TC. Association between the diagnosis-to-treatment interval and overall survival in Taiwanese patients with oral cavity squamous cell carcinoma. European Journal of Cancer. 2017 Feb; 72:226-234.
  34. Wang HY, Chang YL, Cheng CC, Chao MW, Lin SI, Pan SL, Hsu CC, Liu TW, Cheng HC, Tseng CP, Liu SJ, Tsai HJ, Chang HY, Hsu JT. Glucocorticoids may compromise the effect of gefitinib in non-small cell lung cancer. Oncotarget. 2016 Dec; 7(52):85917-85928.
  35. Hung YN, Cheng SH, Liu TW, Chang WC, Chen JS, Tang ST. Trend in and correlates of undergoing radiotherapy in Taiwanese cancer patients’ last month of life. J Pain Symptom Manag. 2016 Sep; 52(3):395-403.
  36. Liu TW, Hung YN, Earle CC, Liu TP, Liu LN, Tang ST. Characteristics and correlates of increasing use of surgery in Taiwanese cancer patients’ last month of life, 2001-2010. Ann Surg. 2016 Aug; 264(2):283-90.
  37. Hsu CH, Tseng CH, Chiang CJ, Hsu KH, Tseng JS, Chen KC, Wang CL, Chen CY, Yen S, Chiu CH, Huang MS, Yu CJ, Tsai YH, Chen JS, Tsai CM, Chou TY, Lin KC, Tsai MH, Lee WC, Ku HY, Liu TW, Yang TY, Chang GC. Characteristics of young lung cancer: Analysis of Taiwan’s nationwide lung cancer registry focusing on epidermal growth factor receptor mutation and smoking status. Oncotarget. 2016 Aug; 7(29):46628-46635. (Project of Core Measurement Indicators)
  38. Hung YN, Liu TW, Lin DT, Chen YC, Chen JS, Tang ST. Receipt of life-sustaining treatments for Taiwanese pediatric patients who died of cancer in 2001 to 2010: A Retrospective Cohort Study. Medicine (Baltimore). 2016 Apr; 95(16):e3461.
  39. Liu TW, Chen LT. S-1 with leucovorin for gastric cancer: How far can it go? Lancet Oncology. 2016 Jan; 17(1):12-14.
  40. Chen MH, Lin J, Hsiao CF, Shan YS, Chen YC, Chen LT, Liu TW, Li CP, Chao Y. A phase II study of sequential capecitabine plus oxaliplatin followed by docetaxel plus capecitabine in patients with unresectable gastric adenocarcinoma: The TCOG 3211 Clinical Trial. Medicine (Baltimore). 2016 Jan;95(3):e2565.
  41. Ou-Yang F, Hsu NC, Juan CH, Huang HI, Moi SH, Chen FM, Liu TW, Hou MF. Breast cancer quality of care in Taiwan in relation to hospital volume: A population-based cohort study. Asia-Pac J Clin Oncol. 2015 Dec; 11(4):308-13. (Project of Core Measurement Indicators)
  42. Tang ST, Liu TW, Wen FH, Hsu C, Chang YH, Chang CS, Sung YC, Hsieh CI, Chang SY, Liu LN, Chiang MC. A Decade of changes in preferences for life-sustaining treatments among terminally ill patients with cancer. J Natl Compr Canc Ne. 2015 Dec; 13(12):1510-8.
  43. Hung YN, Liu TW, Tang ST. Determinants of hospital death for Taiwanese pediatric cancer decedents, 2001–2010. J Pain Symptom Manag. 2015 Nov; 50(5):685-92.
  44. Liu TW, Hung YN, Soong TC, Tang ST. Increasing receipt of high-tech/high-cost imaging and its determinants in the last month of Taiwanese patients with metastatic cancer, 2001-2010: A retrospective cohort study. Medicine (Baltimore). 2015 Aug; 94(32):e1354.
  45. Liu LN, Chen CH, Liu TW, Lin YC, Lee SC, Tang ST. Preferences for aggressive end-of-life care and their determinants among Taiwanese terminally ill cancer patients. Cancer Nurs. 2015 May-Jun; 38(3):E9-18.
  46. Liang PC, Ch’ang HJ, Hsu C, Chen LT, Shih TTF, Liu TW. Perfusion parameters of dynamic contrast-enhanced magnetic resonance imaging predict outcomes of hepatocellular carcinoma receiving radiotherapy with or without thalidomide. Hepatology International. 2015 Apr; 9(2):258-68.
  47. Tang ST, Liu TW, Liu LN, Chiu CF, Hsieh RK, Tsai CM. Physician-patient end-of-life care discussions: Correlates and associations with end-of-life care preferences of cancer patients-a cross-sectional survey study. Palliative Medicine. 2014 Dec; 28(10):1222-30.
  48. Tang ST, Liu TW, Chow JM, Chiu CF, Hsieh RK, Chen CH, Liu LN, Feng WL. Associations between accurate prognostic understanding and end-of-life care preferences and its correlates among Taiwanese terminally ill cancer patients surveyed in 2011-2012. Psycho-Oncology. 2014 Jul; 23(7):780-7.
  49. Hsu C, Tsou HH, Lin SJ, Wang MC, Yao M, Hwang WL, Kao WY, Chiu CF, Lin SF, Lin J, Chang CS, Tien HF, Liu TW, Chen PJ, Cheng AL, Taiwan Cooperative Oncology Group. Chemotherapy-induced hepatitis B reactivation in lymphoma patients with resolved HBV infection: A prospective study. Hepatology. 2014 Jun; 59(6):2092-100. (TCOG T1408 Study)
  50. Wang LW, Hsiao CF, Chen WT, Lee HH, Lin TC, Chen HC, Chen HH, Chien CR, Lin TY,Liu TW. Celecoxib plus chemoradiotherapy for locally advanced rectal cancer: A phase II TCOG study. J Surg Oncol. 2014 May; 109(6):580-5. (TCOG T2207 Study)
  51. Chang HH, Chie WC, Chin YH, Hsu CP, Liu TW, Whang-Peng J. Development and validation of an instrument for the measurement of health-related quality of life based on view of traditional chinese medicine perspective. Journal of Traditional and Complementary Medicine. 2012 Oct; 2(4):295-300.
  52. Liu TW, Chang WC, Wang HM, Chen JS, Koong SL, Hsiao SC, Tang ST. Use of chemotherapy at the end of life among Taiwanese cancer decedents, 2001-2006. Acta Oncol. 2012 Apr; 51(4):505-11.
  53. Chow L, Lin PC, Chang JS, Chu PY, Lee PK, Chen SN, Cheng YM, Lee JC, Chang JY, Liu TW*. Differences in the frequencies of K-ras c12-13 genotypes by gender and pathologic phenotypes in colorectal tumors measured using the allele discrimination method. Environ Mol Mutagen. 2012 Jan; 53(1):22-31. (* corresponding author)
  54. Tang ST, Liu TW, Shyu YI, Huang EW, Koong SL, Hsiao SC. Impact of age on end-of-life care for adult Taiwanese cancer decedents, 2001-2006. Palliative Med. 2012 Jan; 26(1):80-8.
  55. Kuo CC, Liu TW, Chen LT, Shiah HS, Wu CM, Cheng YT, Pan WY, Liu JF, Chen KL, Yang YN, Chen SN, Chang JY. Combination of arsenic trioxide and BCNU synergistically triggers redox-mediated autophagic cell death in human solid tumors. Free Radical Biol Med. 2011 Dec; 51(12):2195-209.
  56. Wang HM, Koong SL, Hsiao SC, Chen JS, Liu TW, Tang ST. Impact of availability of an inpatient hospice unit on the parent hospital’s quality of palliative care for Taiwanese cancer decedents, 2001-2006. J Pain Symptom Manag. 2011 Sep; 42(3):400-9.
  57. Tang ST, Hung YN, Liu TW, Lin DT, Chen YC, Wu SC, Hsu TH. Pediatric end-of-life care for Taiwanese children who died as a result of cancer from 2001 through 2006. Journal of Clinical Oncology. 2011 Mar; 29(7):890-4.
  58. Tang ST, Huang EW, Liu TW, Wang HM, Rau KM, Chen JS. Aggressive end-of-life care significantly influenced propensity for hospice enrollment within the last three days of life for Taiwanese cancer decedents. Journal of Pain and Symptom Management. 2011 Jan; 41(1):68-78.
  59. Tang ST, Huang EW, Liu TW, Wang HM, Chen JS. A population-based study on the determinants of hospice utilization in the last year of life for Taiwanese cancer decedents, 2001-2006. Psycho-oncology. 2010 Nov; 19(11):1213-20.
  60. Wu SC, Chen JS, Wang HM, Hung YN, Liu TW, Tang ST. Determinants of ICU care in the last month of life for Taiwanese cancer decedents, 2001 to 2006. Chest. 2010 Nov; 138(5):1071-7.
  61. Tang ST, Huang EW, Liu TW, Rau KM, Hung YN, Wu SC. Propensity for home death among Taiwanese cancer decedents in 2001-2006, determined by services received at end of life. J Pain Symptom Manag. 2010 Oct; 40(4):566-74.
  62. Tang ST, Tang WR, Liu TW, Lin CP, Chen JS. What really matters in pain management for terminally ill cancer patients in Taiwan. Journal of Palliative Care. 2010 Sep; 26(3):151-8.
  63. Tang ST, Chen CC, Tang WR, Liu TW. Determinants of patient-family caregiver congruence on preferred place of death in Taiwan. J Pain Symptom Manag. 2010 Aug; 40(2):235-45.
  64. Procter M, Suter TM, de Azambuja E, Dafni U, van Dooren V, Muehlbauer S, Climent MA, Rechberger E, Liu TW, Toi M, Coombes RC, Dodwell D, Pagani O, Madrid J, Hall M, Chen SC, Focan C, Muschol M, van Veldhuisen DJ, Piccart-Gebhart MJ. Longer-term assessment of trastuzumab-related cardiac adverse events in the herceptin adjuvant (HERA) trial. Journal of Clinical Oncology. 2010 July; 28(21):3422-8. (BIG HERA Study)
  65. 劉湫美、黃國哲、邱昌芳、劉滄梧*。美國、英國及台灣之癌症診療品質評核。台灣醫學。第14卷第2期,p. 208-16。民國99年3月。(* corresponding author)
  66. Chung KP, Chang YJ, Lai MS, Kuo RN, Cheng SH, Chen LT, Tang R, Liu TW, Shieh MJ. Is quality of colorectal cancer care good enough? Core measures development and its application for comparing hospitals in Taiwan. BMC Health Serv Res. 2010 Jan 27; 10(1):27.
  67. Chen JS, Wang HM, Wu SC, Liu TW, Huang YN, Tang ST. A population-based study on the prevalence and determinants of cardiopulmonary resuscitation in the last month of life for taiwanese cancer decedents, 2001-2006. Resuscitation. 2009 Dec; 80(12):1388-93.
  68. Liu TW, Chen JS, Wang HM, Wu SC, Hung YN, Tang ST. Quality of end-of-life care between medical oncologists and other physician specialists for Taiwanese cancer decedents, 2001-2006. Oncologist. 2009 Dec; 14(12):1232-41.
  69. Tang ST, Wu SC, Huang YN, Chen JS, Huang EW, Liu TW. Determinants of aggressive end-of-life care for taiwanese cancer decedents, 2001 to 2006. J Clin Oncol. 2009 Sep 20; 27(27):4613-8.
  70. Tang ST, Wu SC, Hung YN, Huang EW, Chen JS, Liu TW. Trends in quality of end-of-life care for Taiwanese cancer patients who died in 2000-2006. Ann Oncol. 2009 Feb; 20(2):343-8.
  71. Hsiao CF,Liu TW, Yang CH. Current advanced statistical issues in clinical research — adaptive designs and translational medicine. J Formosa Med Assoc. 2008 Dec; 107(12 Suppl):1-2.
  72. Tang ST, Liu TW, Tsai CM, Wang CH, Chang GC, Liu LN. Patient awareness of prognosis, patient-family caregiver congruence on the preferred place of death, and caregiving burden of families contribute to the quality of life for terminally ill cancer patients in Taiwan. Psycho-oncology. 2008 Dec; 17(12):1202-9.
  73. Liu CY, Liu TW, Liu JS, Hsiao CF, Chen LT. Medical resource utilizations and economic burden in chinese cancer patients with chemotherapy-induced anemia: a populational database study. Chinese J Cancer Res. 2008 Dec; 20(4):307-15.
  74. Hsu C, Hsiung CA, Su IJ, Hwang WS, Wang MC, Lin SF, Lin TH, Hsiao HH, Young JH, Chang MC, Liao YM, Li CC, Wu HB, Tien HF, Chao TY, Liu TW, Cheng AL and Chen PJ. A revisit of prophylactic lamivudine for chemotherapy-associated hepatitis B reactivation in non-hodgkin’s lymphoma: a randomized trial. Hepatology. 2008 Mar; 47(3):844-53. (TCOG T1401 Study)
  75. Liang PC, Ch’ang HJ, Hsu C, Tseng SS, Shih TT, Liu TW*. Dynamic MRI signals in the second week of radiotherapy relate to treatment outcomes of hepatocellular carcinoma: a preliminary result. Liver Int. 2007 May; 27(4):516-28. (corresponding author)
  76. Shiah HS, Chao Y, Chen LT, Yao TJ, Huang JD, Chang JY, Chen PJ, Chuang TR, Chin YH, Whang-Peng J, Liu TW*. Phase I and pharmacokinetic study of oral thalidomide in patients with advanced hepatocellular carcinoma. Cancer Chemoth Pharm. 2006 Nov; 58(5):654-64. (corresponding author)
  77. Tang ST, Liu TW, Lai MS, Liu LN, Chen CH, Koong SL. Congruence of knowledge, experiences, and preferences for disclosure of diagnosis and prognosis between terminally-ill cancer patients and their family caregivers in Taiwan. Cancer Invest. 2006 Jun-Jul; 24(4):360-6.
  78. Ch’ang HJ, Wang CC, Chang AL, Hsu C, Lu YS, Chang MC, Lin JT, Wang HP, Shiah HS, Liu TW, Chang JY, Whang-Peng J, Chen LT. Phase I study of biweekly gemcitabine followed by oxaliplatin and simplified 48-h infusion of fluorouracil/leucovorin for advanced pancreatic cancer. J Gastroen Hepatol. 2006 May; 21(5):874-9.
  79. Shiah HS, Cheng AL, Hsu C, Hsu CH, Liu TW, Chnag JY, Jan CM, Chao Y, Yu WL, Chuang TR, Whang-Peng J, Chen LT. Phase I-II trial of weekly gemcitabine plus high-dose 5-fluorouracil and leucovorin in advanced pancreatic cancer. J Gastroen Hepatol. 2006 Mar; 21(3):531-6.
  80. Wang CC, Chang JY, Liu TW, Lin CY, Yu YC, Hong RL. Phase II study of gemcitabine plus vinorelbine in the treatment of cisplatin-resistant nasopharyngeal carcinoma. Head Neck-J Sci Spec. 2006 Jan; 28(1):74-80.
  81. Shiah HS, Liu TW, Chen LT, Chang JY, Liu JM, Chuang TR, Lee WS, Whang-Peng J. Pulmonary embolism after transcatheter arterial chemoembolization. Eur J Cancer Care (Engl). 2005 Dec; 14(5):440-2.
  82. Tang ST, Liu TW, Lai MS, Liu LN, Chen CH. Concordance of preferences for end-of-life care between terminally ill cancer patients and their family caregivers in Taiwan. J Pain Symptom Manage. 2005 Dec; 30(6):510-8.
  83. Tang ST, Liu TW, Lai MS, McCorkle R. Discrepancy in the preferences of place of death between terminally ill cancer patients and their primary family caregivers in Taiwan. Soc Sci Med. 2005 Oct; 61(7):1560-6.
  84. Chan CH, Liu TW, Chen LT, Chang JY, Whang-Peng J. Long-term complete remission of metastatic gastric cancer after weekly docetaxel, 24 h infusion of high-dose 5-FU/leucovorin and cisplatin. J Gastroen Hepatol. 2005 Sep; 20(9):1470-1.
  85. Chen LT, Liu TW, Chao Y, Shiah HS, Chnag JY, Juang SH, Chen SC, Chuang TR, Chin YH, Whang-Peng J. alpha-fetoprotein response predicts survival benefits of thalidomide in advanced hepatocellular carcinoma. Aliment Pharmacol Ther. 2005 Aug 1; 22(3):217-26.
  86. Lan C, Liu JM, Liu TW, Hsu DH, Liang SC, Chen JR, Whang Peng J. erb-b2 amplification by fluorescence in situ hybridization in breast cancer specimens read as 2+ in immunohistochemical analysis. Am J Clin Pathol. 2005 Jul; 124(1):97-102.
  87. Chan AT, Hsu MM, Goh BC, Hui EP, Liu TW, Millward MJ, Hong RL, Whang-Peng J, Ma BB, To KF, Mueser M, Amellal N, Lin X, Chang AY. Multicenter, phase II study of cetuximab in combination with carboplatin in patients with recurrent or metastatic nasopharyngeal carcinoma. J Clin Oncol. 2005 May; 23(15):3568-76.
  88. Liu JM, Chen LT, Li AF, Wu CW, Lan C, Chung TR, Shiah HS, Lee KD, Liu TW, Peng JW. Prognostic implications of the expression of erbB2, topoisomerase II alpha and thymidylate synthase in metastatic gastric cancer after fluorouracil-based therapy. Jpn J Clin Oncol. 2004 Dec; 34(12):727-32.
  89. Chang JY, Ka WS, Chao TY, Liu TW, Chuang TR, Chen LT. Hepatocellular carcinoma with intra-atrial tumor thrombi: A report of three cases responsive to thalidomide treatment and literature review. Oncology. 2004 Nov; 67(3-4):320-6.
  90. Wang J, Chen LT, Tsang YM, Liu TW, Shih TT. Dynamic contrast-enhanced MRI analysis of perfusion changes in advanced hepatocellular carcinoma treated with an antiangiogenic agent: a preliminary study. AJR Am J Roentgenol. 2004 Sep; 183(3):713-9.
  91. Shih TT, Chang CJ, Tseng WY, Hsiao JK, Shen LC, Liu TW, Yang PC. Effect of calcium channel blockers on vertebral bone marrow perfusion of the lumbar spine. Radiology. 2004 Apr; 231(1):24-30.
  92. Chen LT, Liu TW, Wu CW, Chung TR, Shiah HS, Jan CM, Liu JM, Whang-Peng J, Chang JY. A phase I study of weekly docetaxel, 24-hour infusion of high-dose fluorouracil/leucovorin and cisplatin in patients with advanced gastric cancer. Oncology. 2002 Oct; 63(3):239-47.
  93. Chang JY, Liu JF, Juang SH, Liu TW, Chen LT. Novel mutation of topoisomerase I in endering cells resistant to camptothecin. Cancer Res. 2002 Jul; 62(13):3716-21.
  94. Lee KD, Liu TW, Wu CW, Tiu CM, Liu JM, Chung TR, Chang JY, Whang-Peng J, Chen LT. Non-surgical treatment for afferent loop syndrome in recurrent gastric cancer complicated by peritoneal carcinomatosis: percutaneous transhepatic duodenal drainage followed by 24-hour infusion of high-dose fluorouracil and leucovorin. Ann Oncol. 2002 Jul; 13(7):1151-5.
  95. Chi KH, Chang YC, Guo WY, Leung MJ, Shiau CY, Chen SY, Wang LW, Lai YL, Hsu MM, Lian SL, Chang CH, Liu TW, Chin YH, Yen SH, Perng CH, Chen KY. A phase III study of adjuvant chemotherapy in advanced nasopharyngeal carcinoma patients. Int J Radiat Oncol Biol Phys. 2002 Apr; 52(5):1238-44. (TCOG T1394 Study)
  96. Chen YM, Perng RP, Yang KY, Liu TW, Tsai CM, Ming-Liu J, Whang-Peng J. A multicenter phase II trial of vinorelbine plus gemcitabine in previously untreated inoperable (Stage IIIB/IV) non-small cell lung cancer. Chest. 2000 Jun; 117(6):1583-9.
  97. Hsieh CI, Liu MC, Cheng SH, Liu TW, Chen CM, Chen CM, Tsou MH, Huang AT. Adjuvant sequential chemotherapy with doxorubicin plus cyclophosphamide, methotrexate, and fluorouracil (ACMF) with concurrent radiotherapy in respectable advanced breast cancer. Am J Clin Oncol. 2000 Apr; 23(2):122-7.
  98. Kukhanova M, Liu TW, Pelicano H, Cheng YC. Excision of beta-L- and beta-D-nucleotide analogs from DNA by p53 protein. Nucleosides Nucleotides Nucleic Acids. 2000 Jan-Feb; 19(1-2):435-46.
  99. Cheng SH, Liu TW, Jian JJ, Tsai SY, Hao SP, Huang CH, Liu MC, Yu B, Huang AT. Concomitant chemotherapy and radiotherapy for locally advanced nasopharyngeal carcinoma. Cancer J Sci Am. 1997 Mar-Apr; 3(2):100-6.
  100. Liu JM, Chen YM, Chao Y, Liu TW, Chou CM, Chen LT, Yu WL, Whang-Peng J. Paclitaxel-induced severe neuropathy in patients with previous radiotherapy to the head and neck region. J Natl Cancer Inst. 1996 Jul; 88(14):1000-2.
  101. Kok VC, Liu TW*, Lin HH, Ou H, Cheng SH, Liu MC, Huang AT. Concomitant renal cell carcinoma and metastatic epithelioid angiosarcoma with microangiopathy. J Formos Med Assoc. 1995 Jan-Feb; 94(1-2):48-52. (corresponding author)
  102. Nutter LM, Cheng AL, Hung HL, Hsieh RK, Ngo EO, Liu TW. Menadione: spectrum of anticancer activity and effects on nucleotide metabolism in human neoplastic cell lines. Biochem Pharmacol. 1991 May; 41(9):1283-92.
  103. Lin MT, Chen YC, Liu TW, Tien HF, Liu MC, Wang CH, Shen MC, Liu CH. Treatment of refractory or relapsed adult acute leukemia by using mitoxantrone-containing regimens. Taiwan Yi Xue Hui Za Zhi. 1989 Nov-Dec; 88(11-12):1116-22.
  104. Cheng AL, Chen YC, Wang CH, Su IJ, Hsieh HC, Chang JY, Hwang WS, Su WC, Liu TW, Tien HF, et al. Direct comparisons of peripheral T-cell lymphoma with diffuse B-cell lymphoma of comparable histological grades–should peripheral T-cell lymphoma be considered separately? J Clin Oncol. 1989 Jun; 7(6):725-31.
  105. Cheng AL, Chen YC, Su IJ, Wang CH, Hsieh HC, Chen CL, Lai HS, Liu TW, Tien HF, Shen MC, et al. Adult non-Hodgkin’s lymphoma in Taiwan area: a clinicopathologic study of 123 cases based on working formulation classification. Taiwan Yi Xue Hui Za Zhi. 1989 Feb; 88(2):108-13.
  106. Chen YC, Wang CH, Lin DT, Lui PT, Cheng AL, Liu TW, Tsay W, Tien HF, Liu MC, Chuu WM, et al. Allogeneic bone marrow transplantation in the treatment of leukemia — a preliminary report. Taiwan Yi Xue Hui Za Zhi. 1987 May; 86(5):490-6.
Share Button

Comments are closed.